• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of the American Pharmacists Association: JAPhA >Rosuvastatin: a high-potency HMG-CoA reductase inhibitor.
【24h】

Rosuvastatin: a high-potency HMG-CoA reductase inhibitor.

机译：罗苏伐他汀：一种高效HMG-CoA还原酶抑制剂。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: To summarize the relevant pharmacologic, clinical, and safety data regarding rosuvastatin (Crestor--AstraZeneca), the most recently marketed 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor approved for the treatment of dyslipidemia. DATA SOURCES: Medline search from years 1990 thru 2005 using the keywords HMG-CoA reductase inhibitor, hypercholesterolemia, lipid-lowering agents, rosuvastatin, and statins. Study Selection: Review articles, clinical trials, case reports, abstracts, and data on file from the manufacturer concerning rosuvastatin and other statins were considered for inclusion. DATA EXTRACTION: English-language studies were selected for inclusion. DATA SYNTHESIS: Multiple clinical trials have revealed that use of rosuvastatin is associated with greater reductions in low-density lipoprotein cholesterol (LDL-C) across the dose range of 5-40 mg/day than any other currently available statins. Rosuvastatin also significantly increases high-density lipoprotein cholesterol and reduces triglycerides significantly as well. In clinical trials, rosuvastatin was well tolerated, with a low incidence of adverse events and a safety profile similar to that of the other marketed statins. At present, no large-scale primary or secondary prevention clinical trials document either long-term safety of rosuvastatin or its effectiveness in preventing coronary events. CONCLUSION: Compared with other statins, rosuvastatin offers the greatest lipid-lowering efficacy at the lowest dose in treating patients with dyslipidemia and with a similar safety profile over the short-term. Rosuvastatin may allow more patients to achieve their LDL-C goals than any other statin and at a lower dose than other agents.
机译：目的：总结有关瑞舒伐他汀（瑞舒伐他汀（Crestor-AstraZeneca））的相关药理学，临床和安全性数据，瑞舒伐他汀是最近被批准用于治疗血脂异常的3-羟基-3-甲基戊二酰辅酶A（HMG-CoA）还原酶抑制剂。数据来源：Medline在1990年至2005年期间使用关键字HMG-CoA还原酶抑制剂，高胆固醇血症，降脂药，瑞舒伐他汀和他汀类药物进行搜索。研究选择：考虑纳入罗舒伐他汀和其他他汀类药物的复习文章，临床试验，病例报告，摘要和制造商的归档数据。数据提取：选择英语研究作为纳入。数据综合：多项临床试验表明，在5-40 mg /天的剂量范围内，罗苏伐他汀的使用与低密度脂蛋白胆固醇（LDL-C）的降低相比，可比任何其他现有的他汀类药物更大。瑞舒伐他汀还显着增加高密度脂蛋白胆固醇，并显着降低甘油三酸酯。在临床试验中，瑞舒伐他汀耐受性良好，不良事件发生率低，安全性与其他市售他汀类药物相似。目前，尚无大规模的一级或二级预防临床试验证明瑞舒伐他汀的长期安全性或其在预防冠心病方面的有效性。结论：与其他他汀类药物相比，瑞舒伐他汀在治疗血脂异常患者中以最低剂量提供最大的降脂功效，并且短期内具有相似的安全性。与任何其他他汀类药物相比，瑞舒伐他汀可以使更多的患者达到其LDL-C目标，并且剂量要比其他药物低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号